A Promise In The Making
Bangladesh’s garments story is one of scale, cost advantage and global market penetration. It transformed a fragmented apparel industry into a $40+ billion export engine in a few decades. The obvious strategic question for policymakers, manufacturers and investors is simple: can pharmaceuticals be the next garments? The short answer: yes but only with targeted capability upgrades, regulatory sophistication and strategic investment.
In fiscal 2024-25 Bangladesh’s pharmaceutical exports reached roughly US$213 million, a notable increase from previous years but still a fraction of what garments deliver. Growth is visible monthly surges, entry into new markets and expanding product baskets, yet the industry faces unique technical, regulatory and supply-chain barriers that make a “garments-style” leap non-trivial.
This article unpacks the real opportunity, the compliance and capability gaps, and a consultant’s playbook, a practical roadmap for exporters, investors and policymakers who want to turn potential into sustained export scale.
Where Bangladesh Stands Today
The headline numbers are encouraging. After years of steady growth, pharmaceutical exports exceeded US$200m in FY2024-25, marking incremental progress in both volume and product sophistication. There were record months within the fiscal year (e.g., November 2024 showed a sharp spike) and notable year-on-year increases across several product categories. Yet growth in 2024-25 was modest (about 4% year-on-year against FY2023-24), indicating momentum but also constraints that limit faster scaling.
Domestic demand now dominates local production. Bangladesh meets roughly 97% of local pharmaceutical needs and local firms are exporting to over a hundred markets. Several domestic leaders (Square, Incepta, Beximco and others) have acquired WHO-GMP and other international accreditations; some, notably Beximco, have secured important regulatory clearances for export to highly regulated markets. These credentials are critical stepping stones for global market access.
But even with these wins, the global prize is large: the worldwide generics and biosimilars markets are worth many tens of billions and competitive entry requires more than low unit cost. It demands regulatory credentials, consistent quality, API (active pharmaceutical ingredient) security, and supply chains that can handle cold-chain, sterile injectables and complex formulations that buyers in regulated markets require.
Where Opportunity Shines
-
Rising global demand for affordable generics and biosimilars
Developed economies continue to seek cost-effective generic alternatives to branded drugs; middle-income markets want better access to complex therapies at lower cost. Bangladesh, with manufacturing scale, a large domestic market and a tradition of generic production, can leverage global demand if it can meet regulatory and quality bars.
-
Product diversification beyond simple generics
Historically, Bangladesh’s exports focused on standard formulations. The new frontier is complex generics lyophilized injectables, inhalers (MDIs/DPI), hormones, oncology injectables, and some biologics higher value items that demand stringent production, cold-chain and regulatory control. Local firms are beginning to invest in these categories.
-
Regional and developing-market penetration
Many Bangladesh manufacturers already export to South and Southeast Asia, parts of Africa and the Middle East. Scaling in these markets where regulatory thresholds may be lower than the EU/US but demand is rising offers an achievable near-term growth path while more complex compliance capabilities mature.
The Compliance Barrier: The Hard Truth
Four compliance hurdles distinguish pharmaceuticals from garments:
-
Global regulatory access (EU/US/Japan)
Pharmaceuticals must clear high bars: dossier quality, Good Manufacturing Practice (GMP) certifications, stability data, pharmacovigilance systems, and reliable batch-to-batch quality. Even when production quality is high, documentation and regulatory affairs capability (preparing dossiers, post-market surveillance, responding to regulators) are frequently weaker than in mature exporters. The result: product approvals take longer, and access to high-value markets remains limited.
-
API dependence and supply security
Most Bangladeshi drugmakers import a large share of APIs. Global API supply concentration (notably in China and India) means price and availability risk. For high-value biologics and sterile injectables, API scarcity or quality variability is fatal. Securing API long-term supply through backward integration, joint ventures, or diversification is essential.
-
R&D and formulation capability
Moving from first-line generics to complex generics and biosimilars requires R&D investments that typical generic players have not historically prioritized. Capability gaps include formulation development, bioequivalence studies, stability testing and clinical trial management for biosimilars.
-
Cold chain and sterile capacity
Some strategic growth areas (biologics, vaccines, insulin) demand cold-chain and sterile fill/finish facilities. Building and certifying these is capital-intensive and requires operational discipline, making the margin of error small.
These compliance realities are not hypothetical; they are why some products clear and many do not. They are also the reasons why a garments-style leap which largely relied on scale and relatively lower product complexity is not directly replicable in pharma without targeted capability building.
Stories From The Field
Two patterns repeat across successful pharma exporters:
-
Certification first, market second
Firms that prioritized WHO-GMP, EU-GMP and targeted US FDA validations and then aligned sales strategy to those certifications found access into higher-value markets and premium pricing. Beximco’s regulatory progress is a case in point.
-
Stepwise market entry
Rather than racing straight for regulated markets, many companies scale into regional markets with increasing regulatory stringency. This builds technical capability, generates foreign exchange, and refines compliance processes before tackling the EU/US dossier challenge.
A Consultant’s Playbook: Five Strategic Moves
If Bangladesh wants to transform pharmaceutical exports from promising to powerhouse, firms and policy actors should coordinate on this five-point playbook:
-
Build a “Regulatory Capability Engine”
Invest in teams (or partner with CROs/consultancies) that can prepare world-class dossiers, manage pharmacovigilance and run post-approval commitments. Governments can co-fund centers of excellence that provide shared regulatory services for SMEs.
-
Prioritize API security through partnerships or local API hubs
Encourage backward integration, incentivize joint ventures with API producers, and develop bonded API parks. Public-private financing (tax holidays, concessional loans) for API parks would reduce dependence and stabilize costs.
-
Target product ladders, not markets
Design a product progression: start with neighboring markets and simple formulations; move to complex formulations (inhalers, injectables); then target regulated markets once dossier and pharmacovigilance capabilities mature. This reduces risk and maximizes learning.
-
Invest in sterile and cold-chain capacity as shared infrastructure
Encourage multi-tenant sterile fill/finish and cold-chain facilities. Shared infrastructure reduces upfront capex for any one manufacturer and helps multiple players scale simultaneously.
-
Leverage trade diplomacy and buyer partnerships
Use trade promotion (EPB, BAPI) to secure long-term offtake agreements with buyers in Africa, Southeast Asia and the Middle East. Pair market entry with WHO pre-qualification and buyer audits to accelerate trust.
Financial and Investment Considerations
Scaling pharma exports requires different capital dynamics than garments. Returns are often higher per unit, but compliance, validation and the timeline to approval are longer. This argues for mixed financing approaches:
-
Patient capital (VC/PE with long horizons) for complex generics and biologics.
-
Concessional loans & export credit to finance certification, international audits and regulatory filing costs.
-
Public incentives: matching grants for WHO-GMP upgrades, R&D tax credits for generic formulation innovation, and expedited customs for export batches to reduce working capital pressure.
Bangladesh has seen increasing FDI in pharma; the task is to structure incentives to attract not just greenfield plants, but technology partnerships and API investments.
Policy Levers
- Fast-track GMP & dossier support create a single-window regulatory helpdesk to speed international dossier preparation.
- API park policy land, tax and infrastructure to attract API manufacturers to produce raw materials locally or regionally.
- Trade facilitation negotiated mutual recognition agreements for GMP inspections, expedited shipping for export consignments, and export finance support.
- Skills & R&D ecosystem fund university–industry consortia for formulation science, bioequivalence labs, and stability study capacity.
These are not light policy asks. They require interagency cooperation between trade, health, industry and finance ministries but they are precisely the kind of interventions that made garments competitive decades ago.
Risks to Watch
-
Regulatory failure risk
A single GMP failing inspection can shut market access for years. Robust internal QA is therefore non-negotiable.
-
API geopolitics
Concentration of API supply in one country can create vulnerability. Diversify.
-
Financing Gap
Small and medium producers may lack the capital to climb the quality ladder; without financing, the industry will fragment into low-value and a small set of high-value players.
-
Talent Gap
Regulatory affairs specialists, bioprocess engineers and quality scientists are not yet abundant locally; building talent is mission critical.
Bangladesh has ingredients that make pharmaceutical export scale plausible: proven manufacturing competence, a mature domestic market, rising firm ambition, and some international certifications already in place. But pharmaceuticals are not garments. The path to global scale is longer, more technical, and more dependent on regulatory credibility and complex supply chains.
A practical, staged strategy build capability, secure API supply, invest in shared sterile/cold infrastructure, and pursue regional markets first gives Bangladesh the best chance to replicate the export miracle it achieved with garments, albeit on a different timeline and with different policy and capital demands.
Success will not be a single breakthrough. It will be a series of disciplined investments in quality, regulation, and supply-chain security that over a decade turn $200m-level exports into a multi-billion-dollar industry that complements the garments sector and deepens Bangladesh’s place in the global health supply chain. Liman Finthra
Reference
- The Daily Star 2025, ‘Pharma exports more than double in seven years’, The Daily Star, 11 July. [Accessed 29 Oct 2025].
- The Daily Star 2024, ‘Pharma exports hit record high in Nov’, The Daily Star, 13 Dec. [Accessed 29 Oct 2025].
- The Daily Star 2025, ‘Despite April decline, pharma exports maintain upward trend’, The Daily Star, 13 May. [Accessed 29 Oct 2025]. The Daily Star
- Beximco Pharmaceuticals PLC 2015–2025, Company announcements and regulatory approvals, Beximco Pharma. [Accessed 29 Oct 2025].
- ResearchGate 2025, F. Khatun, ‘Technological Readiness of Bangladesh’s Pharmaceutical Industry’ (report), CPD/Research. [Accessed 29 Oct 2025].
- Financial Express 2025, ‘Drug makers’ growth hinges on whether they can raise money’, The Financial Express, 16 June. [Accessed 29 Oct 2025]. The Financial Express
- PharmabossBD 2025, ‘Bangladesh Pharmaceutical Export Market 2025’, PharmabossBD, 30 July. [Accessed 29 Oct 2025].
